No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose

Journal of Urology

Volumn 170, Issue 6 I, 2003, Pages 2296-2301

  Martinez, Alvaro ^a   Galalae, Razvan ^b   Gonzalez, Jose ^a   Mitchell, Christina ^a   Gustafson, Gary ^a   Kovacs, Gyorgy ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Androgen antagonists; Brachytherapy; Prostate; Prostatic neoplasms

Indexed keywords

ANDROGEN; ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN SUPPRESSION THERAPY; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; DRUG COST; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

EID: 0242523827     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000096709.05800.48     Document Type: Article

References (21)

1. Horwitz, E. M., Winter, K., Hanks, G. E., Lawton, C. A., Russell, A. H. and Mitchell, M.: Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys, 49: 947, 2001
2. Laverdiere, J., Gomez, J. L., Cusan, L., Suburu, E. R., Diamond, P., Lemay, M. et al: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys, 37: 247, 1997
3. Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G. et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337: 295, 1997
4. Roach, M., Lu, J., Pilepich, M., Asbell, S., Mohuidden, M., Terry, R. et al: Predicting survival and the role of androgen suppressive therapy (AST): Radiation Therapy Oncology Group (RTOG) phase III randomized prostate cancer trials. Int J Radiat Oncol Biol Phys, 42: 177, 1998
5. Hanks, G. E., Lu, J. D., Machtay, M., Venkatesan, V. M., Pinover, W. H., Byhardt, R. W. et al: RTOG 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys, 48: 112, 2000
6. Zelefsky, M. J., Leibel, S. A., Gaudin, P. B., Kutcher, G. J., Fleshner, N. E., Venkatramen, E. S. et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys, 41: 491, 1998
7. Hanks, G. E., Hanlon, A. L., Schultheiss, T. E., Pinover, W. H., Movsas, B., Epstein, B. E. et al: Dose escalation with 3-D conformal treatment: five-year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys, 41: 501, 1998
8. Martinez, A. A., Gustfson, G., Gonzalez, J., Armour, E., Mitchell, C., Edmundson, G. et al: Dose escalation using conformal high-dose-rate brachytherapy improves the outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys, 53: 316, 2002
9. Martinez, A. A., Yan, D., Lockman, D., Brabbins, D., Kota, K., Sharpe, M. et al: Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. Int J Radiat Oncol Biol Phys, 50: 1226, 2001
10. Lee, L. N., Stock, R. G. and Stone, N. N.: Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys, 52: 444, 2002
11. Blasko, J. C., Ragde, H., Grimm, P., Sylvester, I. and Cavanagh, W.: Potential for neoadjuvant hormonal therapy with brachytherapy for prostate cancer. Mol Urol, 1: 207, 1997
12. Stromberg, J., Martinez, A., Gonzalez, J., Edmundson, G., Ohanian, N., Vicini, F. et al: Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys, 33: 161, 1995
13. Galalae, R. M., Kovacs, G., Schultze, J., Loch, T., Rzehak, P., Wilhelm, R. et al: Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advance prostate cancer. Int J Radiat Oncol Biol Phys, 52: 81, 2002
14. Mate, T. P., Gottesman, J. E., Hatton, J., Gribble, M. and Van Hollebeke, L.: High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys, 41: 525, 1998
15. Borghede, B., Hedelin, H., Holmang, S., Johansson, K. A., Aldenborg, F., Pettersson, S. et al: Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol, 44: 237, 1997
16. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457, 1958
17. Brenner, D. J., Martinez, A. A., Edmundson, G. K., Mitchell, C., Thames, H. D. and Armour, E. P.: Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/ beta ratio) similar to late-responding normal tissues. Int J Radiat Oncol Biol Phys, 52: 6, 2002
18. Bertermann, H. and Brix, F.: Ultrasonically guided interstitial high dose brachytherapy with iridium 192: technique and preliminary results in locally confined prostate cancer. In: Brachytherapy HDR and LDR. Edited by A. Martinez, C. Orton and R. F. Mould. Columbia, Maryland: Nucletron Corp., chapt. 24, pp. 282-303, 1990
19. Aus, G., Abrahamsson, P.-A., Ahlgren, G., Hugosson, J., Lundberg, S., Schain, M. et al: Hormonal treatment before radical prostatectomy: a 3-year followup. J Urol, 159: 2013, 1998
20. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr. and Puras-Baez, A. for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol, 154: 424, 1995
21. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A. et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 280: 969, 1998